The FDA never approved a drug derived from the cannabis plant before
As intriguing a story as legalization makes in Canada, it may not be as big of a game changer as what GW Pharmaceuticals (NASDAQ:GWPH) looks poised to do in the United States.
You see, the U.K.-based cannabinoid-based drug developer has its lead drug, a cannabidiol (CBD)-based oral medicine known as Epidiolex, under review by the Food and Drug Administration (FDA) for the treatment of two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. CBD is the nonpsychoactive component of the cannabis plant that’s perhaps best known for its perceived medical benefits.
At no point in history has the FDA ever approved a drug derived from the cannabis plant. Sure, synthetic versions of tetrahydrocannabinol (THC), the psychoactive component of the cannabis plant that gets you “high,” have been given the OK, but never a cannabinoid-based drug derived directly from the cannabis plant.
To Read The Rest Of This Article On Motley Fool, Click Here